CC BY 4.0 · Synlett
DOI: 10.1055/a-2562-7204
letter
Small Molecules in Medicinal Chemistry

Benzylhydroxamic Acids as IRAP Inhibitors: Sulfonamide Variations

a   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
,
Marcus Söderström
a   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
,
Lorenzo Jacopo Ilic Balestri
b   Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
,
Rubén Prieto-Díaz
c   Department of Cell and Molecular Biology, Biomedical Centre, Uppsala University, Box 596, 751 24, Uppsala, Sweden
,
Hugo Gutierrez-de-Teran
c   Department of Cell and Molecular Biology, Biomedical Centre, Uppsala University, Box 596, 751 24, Uppsala, Sweden
d   Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), Health Research Institute of Asturias (ISPA), Av. del Hospital Universitario, s/n, 33011 Oviedo, Asturias, Spain
,
b   Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
,
Mathias Hallberg
e   The Beijer Laboratory, Department of Pharmaceutical Biosciences, Neuropharmacology and Addiction Research, Biomedical Centre, Uppsala University, Box 591, 751 24 Uppsala, Sweden
,
a   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
,
a   The Beijer Laboratory, Science for Life Laboratory, Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Box 574, 751 23 Uppsala, Sweden
› Author Affiliations

Computations were performed with resources provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS), partially funded by the Vetenskapsrådet (Swedish Research Council) through grant agreement no. 2022-06725, the Kjell och Märta Beijers Stiftelse, Vetenskapsrådet (Swedish Research Council) through grants no. 2021-03293 and 2022-04831 and the Swedish Brain Foundation through grant FO2024-0317-HK-70. Additional support is acknowledged from the Swedish Strategic Research Program eSSENCE.


Abstract

Small-molecule inhibitors of the zinc metalloprotease insulin-regulated aminopeptidase (IRAP, EC 3.4.11.3), are a promising new class of potential cognitive enhancers for the treatment of neurodegenerative disorders such as Alzheimer’s disease. Previous studies identified a series of sulfonamide-substituted benzylhydroxamic acids with fair BBB permeability, no indication of efflux and subnanomolar potency. We herein report our further structural optimization of this compound series focusing on various alterations to the sulfonamide group. Notably, introduction of dihydropyridopyrimidine provided the most active small-molecule inhibitor compound reported to date, with an IC50 value of 34 nM. Molecular modeling studies, based on free energy perturbation simulations, show that the accommodation of the explored substituents on the binding mode proposed explain the experimental SAR herein reported and provide a rationale for the enhanced affinity of the optimized compounds.

Supporting Information



Publication History

Received: 31 January 2025

Accepted: 19 March 2025

Accepted Manuscript online:
19 March 2025

Article published online:
15 April 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 
  • References

  • 1 Tsujimoto M, Hattori A. Biochim. Biophys. Acta, Proteins Proteomics 2005; 1751: 9
  • 2 Georgiadis D, Ziotopoulou A, Kaloumenou E, Lelis A, Papasava A. Front. Pharmacol. 2020; 11: 585838
  • 3 Hallberg M, Larhed M. Front. Pharmacol. 2020; 11: 590855
  • 4 Barlow N, Thompson PE. Front. Pharmacol. 2020; 11: 585930
  • 5 Wallis MG, Lankford MF, Keller SR. Am. J. Physiol. Endocrinol. Metab. 2007; 293: E1092
  • 6 Mizutani S. Nagoya J. Med. Sci. 1998; 61: 85
  • 7 Herbst JJ, Ross SA, Scott HM, Bobin SA, Morris NJ, Lienhard GE, Keller SR. Am. J. Physiol. 1997; 272: E600
  • 8 Matsumoto H, Rogi T, Yamashiro K, Kodama S, Tsuruoka N, Hattori A, Takio K, Mizutani S, Tsujimoto M. Eur. J. Biochem. 2000; 267: 46
  • 9 Matsumoto H, Nagasaka T, Hattori A, Rogi T, Tsuruoka N, Mizutani S, Tsujimoto M. Eur. J. Biochem. 2001; 268: 3259
  • 10 Alescio-Lautier B, Paban V, Soumireu-Mourat B. Eur. J. Pharmacol. 2000; 405: 63
  • 11 Seyer B, Diwakarla S, Burns P, Hallberg A, Grӧnbladh A, Hallberg M, Chai SY. J. Neurochem. 2020; 153: 485
  • 12 Albiston AL, Morton CJ, Ng HL, Pham V, Yeatman HR, Ye S, Fernando RN, De Bundel D, Ascher DB, Mendelsohn FA. O, Parker MW, Chai SY. FASEB J. 2008; 22: 4209
  • 13 Borhade SR, Rosenström U, Sävmarker J, Lundbäck T, Jenmalm-Jensen A, Sigmundsson K, Axelsson H, Svensson F, Konda V, Sköld C, Larhed M, Hallberg M. ChemistryOpen 2014; 3: 256
  • 14 Diwakarla S, Nylander E, Grönbladh A, Vanga SR, Shamsudin Y, Gutiérrez-de-Terán H, Sävmarker J, Ng L, Pham V, Lundbäck T, Jenmalm-Jensen A, Svensson R, Artursson P, Zelleroth S, Engen K, Rosenström U, Larhed M, Åqvist J, Chai SY, Hallberg M. ACS Chem. Neurosci. 2016; 7: 1383
  • 15 Papakyriakou A, Zervoudi E, Tsoukalidou S, Mauvais F.-X, Sfyroera G, Mastellos DC, van Endert P, Theodorakis EA, Vourloumis D, Stratikos E. J. Med. Chem. 2015; 58: 1524
  • 16 Kokkala P, Mpakali A, Mauvais F.-X, Papakyriakou A, Daskalaki I, Petropoulou I, Kavvalou S, Papathanasopoulou M, Agrotis S, Fonsou T.-M, van Endert P, Stratikos E, Georgiadis D. J. Med. Chem. 2016; 59: 9107
  • 17 Engen K, Vanga SR, Lundbäck T, Agalo F, Konda V, Jensen AJ, Åqvist J, Gutiérrez-de-Terán H, Hallberg M, Larhed M, Rosenström U. ChemistryOpen 2020; 9: 325
  • 18 Vourloumis D, Mavridis I, Athanasoulis A, Temponeras I, Koumantou D, Giastas P, Mpakali A, Magrioti V, Leib J, van Endert P, Stratikos E, Papakyriakou A. J. Med. Chem. 2022; 65: 10098
  • 19 Engen K, Lundbäck T, Yadav A, Puthiyaparambath S, Rosenström U, Gising J, Jenmalm-Jensen A, Hallberg M, Larhed M. Int. J. Mol. Sci. 2024; 25: 2516
  • 20 Gising J, Honarnejad S, Bras M, Baillie GL, McElroy SP, Jones PS, Morrison A, Beveridge J, Hallberg M, Larhed M. Int. J. Mol. Sci. 2024; 25: 4084
  • 21 Beveridge J, Söderström M, Prieto-Díaz R, Gutierrez-de-Teran H, Odell LR, Hallberg M, Larhed M, Gising J. Eur. J. Med. Chem. Rep. 2024; 12: 100215
  • 22 Hermans SJ, Ascher DB, Hancock NC, Holien JK, Michell BJ, Chai SY, Morton CJ, Parker MW. Protein Sci. 2015; 24: 190
  • 23 Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, Abel R, Friesner RA, Harder ED. J. Chem. Theory Comput. 2021; 17: 4291
  • 24 Jespers W, Esguerra M, Åqvist J, Gutiérrez-de-Terán H. J. Cheminform. 2019; 11: 26
  • 25 Bauer P, Barrozo A, Purg M, Amrein BA, Esguerra M, Wilson PB, Major DT, Åqvist J, Kamerlin SC. L. SoftwareX 2018; 7: 388
  • 26 Edwards MP, Price DA. Annu. Rep. Med. Chem. 2010; 45: 380